Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Eagle Pharmaceuticals stock opened at $0.50 on Tuesday. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.81. The stock has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $2.89.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of EGRX. AIGH Capital Management LLC raised its holdings in shares of Eagle Pharmaceuticals by 2.1% during the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after purchasing an additional 25,000 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at $971,000. RBF Capital LLC raised its stake in Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $453,000. Finally, DGS Capital Management LLC boosted its stake in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares during the last quarter. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.